Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Batoclimab in Thyroid Eye Disease
2022-002839-66Phase 3Withdrawn
- Sponsor
- Immunovant, Inc.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of batoclimab in Graves Orbitopathy (GO) (2 arms), sponsored by Immunovant, Inc. Primary endpoint: Duration of proptosis response off treatment. Planned start Dec 2022; status: withdrawn.
02
Drugs
batoclimab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2022-002839-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002839-66.